LivaNova (NASDAQ:LIVN) Upgraded at Barclays

Barclays upgraded shares of LivaNova (NASDAQ:LIVN) to a strong-buy rating in a report published on Wednesday,Zacks reports.

Several other analysts also recently issued reports on the stock. Freedom Capital raised shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Mizuho raised their target price on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Weiss Ratings upgraded shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, August 18th. KeyCorp boosted their target price on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Finally, Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.75.

LivaNova Stock Up 0.6%

Shares of LIVN stock opened at $76.39 on Wednesday. The stock’s 50 day simple moving average is $78.78 and its 200 day simple moving average is $75.01. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45. LivaNova has a twelve month low of $48.82 and a twelve month high of $85.76. The company has a market capitalization of $4.21 billion, a price-to-earnings ratio of 22.60 and a beta of 0.87.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. The firm had revenue of $390.59 million during the quarter, compared to analysts’ expectations of $380.50 million. During the same quarter in the prior year, the business earned $1.05 earnings per share. The company’s revenue was up 10.8% on a year-over-year basis. As a group, research analysts predict that LivaNova will post 3.78 EPS for the current year.

Insider Activity

In related news, Director Francesco Bianchi sold 3,500 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $78.01, for a total transaction of $273,035.00. Following the transaction, the director directly owned 4,434 shares in the company, valued at $345,896.34. The trade was a 44.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Brooke Story sold 2,300 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the transaction, the director owned 7,488 shares in the company, valued at $609,672.96. This represents a 23.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 7,450 shares of company stock valued at $591,839. 0.35% of the stock is owned by corporate insiders.

Institutional Trading of LivaNova

Several institutional investors have recently modified their holdings of LIVN. Allworth Financial LP increased its position in shares of LivaNova by 93.5% during the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Farther Finance Advisors LLC lifted its position in LivaNova by 59.7% in the third quarter. Farther Finance Advisors LLC now owns 452 shares of the company’s stock worth $35,000 after purchasing an additional 169 shares during the period. Public Employees Retirement System of Ohio bought a new position in LivaNova in the second quarter worth $37,000. EverSource Wealth Advisors LLC boosted its stake in LivaNova by 103.6% during the first quarter. EverSource Wealth Advisors LLC now owns 1,623 shares of the company’s stock worth $103,000 after buying an additional 826 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in LivaNova during the fourth quarter worth $116,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and markets technologies for the treatment of cardiovascular and neurological conditions. The company’s principal businesses are organized around its Cardiopulmonary and Neuromodulation segments.

Its cardiopulmonary portfolio includes heart-lung machines, oxygenators, perfusion systems and other equipment used during cardiopulmonary bypass procedures, as well as technologies designed to support cardiac surgery and related clinical applications.